Semax — Research Peptide

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4–7) combined with the Pro-Gly-Pro (PGP) sequence. It has been studied primarily for its potential effects on cognition, memory, neuroprotection, neuroplasticity and neurological recovery.

Semax is particularly interesting in neuroscience research because studies suggest it can influence BDNF and other neurotrophic signalling pathways associated with neuronal survival and plasticity.

Key Research Areas

Cognition, Learning & Memory
Experimental research has investigated Semax for its effects on learning, memory formation and cognitive performance. Animal studies have reported changes in learning behaviour alongside alterations in neurotrophic signalling.

BDNF & Neuroplasticity
One of the most researched aspects of Semax is its relationship with brain-derived neurotrophic factor (BDNF). BDNF plays an important role in neuronal survival, synaptic plasticity, learning and memory. Research in rats has demonstrated changes in BDNF expression and BDNF protein levels following Semax administration.

Neuroprotection Research
Semax has been investigated in experimental models involving cerebral ischemia and neurological injury. Research has examined its influence on neuroprotective, inflammatory and neurotransmitter-related pathways following ischemic injury.

NGF & Neurotrophic Signalling
In addition to BDNF, researchers have studied Semax’s effects on nerve growth factor (NGF) and related neurotrophin pathways. Experimental results indicate that Semax can produce region- and time-dependent changes in BDNF and NGF gene expression.

Neurological Recovery Research
Semax has also undergone human clinical research in areas including ischemic stroke and neurological rehabilitation. Some studies have reported associations with increased BDNF and improved functional recovery; however, much of this clinical literature comes from Russia and does not establish Semax as a generally approved treatment internationally.

How Semax Is Being Studied

Semax appears to affect several neurological signalling systems rather than operating through one established mechanism. Current research has investigated its effects on:

• BDNF and TrkB signalling
• Nerve Growth Factor (NGF)
• Neuroplasticity and synaptic signalling
• Neurotransmitter-related gene expression
• Cellular responses to hypoxia and ischemia
• Inflammatory and neuroimmune pathways
• Learning and memory processes